Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion

Pancreas

Volumn 36, Issue 3, 2008, Pages 241-248

  Mitsunaga, Shuichi ^a   Kinoshita, Taira ^a   Hasebe, Takahiro ^a   Nakagohri, Toshio ^a   Konishi, Masaru ^a   Takahashi, Shinichiro ^a   Gotohda, Naoto ^a   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cachexia; Cholinesterase; Nerve invasion; Nerve plexus invasion; Pancreatic cancer; Systemic disorder

Indexed keywords

CA 19-9 ANTIGEN; CHOLINESTERASE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER INVASION; CANCER RECURRENCE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; NERVE PLEXUS INVASION; PANCREAS CANCER; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PERITONEUM; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROGNOSIS; SYSTEMIC DISEASE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CHOLINESTERASES; ENTERIC NERVOUS SYSTEM; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; RECURRENCE;

EID: 41149097263     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31815b6b2b     Document Type: Article

References (29)

1. Barber MD, Barber MD, Ross JA, et al. Changes in nutritional, functional, and inflammatory markers in advanced pancreatic cancer. Nutr Cancer. 1999;35:106-110.
2. Gianotti L, Braga M, Radaelli G, et al. Lack of improvement of prognostic performance of weight loss when combined with other parameters. Nutrition. 1995;11:12-16.
3. Tas F, Aykan F, Alici S, et al. Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease. Am J Clin Oncol. 2001;24:547-550.
4. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer. 1995;75:2613-2622.
5. Costamagna G, Pandolfi M. Endoscopic stenting for biliary and pancreatic malignancies. J Clin Gastroenterol. 2004;38:59-67.
6. Wehrmann T, Riphaus A, Frenz MB, et al. Endoscopic pancreatic duct stenting for relief of pancreatic cancer pain. Eur J Gastroenterol Hepatol. 2005;17:1395-1400.
7. Mitsunaga S, Hasebe T, Iwasaki M, et al. Important prognostic histological parameters for patients with invasive ductal carcinoma of the pancreas. Cancer Sci. 2005;96:858-865.
8. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
9. Scott HR, McMillan DC, Brown DJ, et al. A prospective study of the impact of weight loss and the systemic inflammatory response on quality of life in patients with inoperable non-small cell lung cancer. Lung Cancer. 2003;40:295-299.
10. Cancer Therapy Evaluation Program. Common Toxicity Criteria version 2.0. CTEP Web site. Available at: http://ctep.info.nih.gov. Accessed January 15, 2007.
11. Child CG III. The Liver and Portal Hypertension. Philadelphia, PA: WB Saunders; 1964.
12. Japan Pancreas Society. The Classification of Pancreatic Carcinoma. 1st English ed. Tokyo, Japan: Kanehara; 1996.
13. Sobin HL, Wiitekind C. TNM Classification of Malignant Tumors. 6th ed. New York: Wiley-Liss; 2002.
14. Hamilton RS, Aaltonen AL. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. Lyon, France: IARC Press; 2000.
15. Garello E, Battista S, Bar F, et al. Evaluation of hepatic function in liver cirrhosis: clinical utility of galactose elimination capacity, hepatic clearance of D-sorbitol, and laboratory investigations. Dig Dis Sci. 1999;44:782-788.
16. Maltoni M, Pirovano M, Nanni O, et al. Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage. 1997;13:1-9.
17. Brown SS, Kalow W, Pilz W, et al. The plasma cholinesterases: a new perspective. Adv Clin Chem. 1981;22:1-123.
18. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646-649.
19. Mitsunaga S, Hasebe T, Kinoshita T, et al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol. 2007;31:1636-1644.
20. Nakao A, Harada A, Nonami T, et al. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas. 1996;12:357-361.
21. Hishinuma S, Ogata Y, Tomikawa M, et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg. 2006;10:511-518.
22. Sperti C, Pasquali C, Piccoli A, et al. Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg. 1997;21:195-200.
23. Devita VT, Hellman S, Rosenberg SA. CANCER Principles and Practice of Oncology. 7th ed. Tokyo, Japan: Lippincott Williams and Wilkins; 2004.
24. Carpenter MB, Sutin J. Human Neuroanatomy. 8th Japanese ed. Niigata, Japan: Nishimura Co., Ltd.; 1995.
25. Puschel GP. Control od hepatocyte metabolism by sympathetic and parasympathetic hepatic nerve. Anat Rec A Discov Mol Cell Evol Biol. 2004;280:854-867.
26. Carreno FR, Seelaender MCL. Liver denervation affects hepatocyte mitochondrial fatty acid transport capacity. Cell Biochem Funct. 2004;22:9-17.
27. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367.
28. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743.
29. Ziske C, Schlie C, Gorschluter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413-1417.